BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27889530)

  • 1. Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.
    Vemula SV; Maxwell JW; Nefedov A; Wan BL; Steve J; Newhard W; Sanchez RI; Tellers D; Barnard RJ; Blair W; Hazuda D; Webber AL; Howell BJ
    Antiviral Res; 2017 Mar; 139():161-170. PubMed ID: 27889530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.
    Brogdon J; Ziani W; Wang X; Veazey RS; Xu H
    Sci Rep; 2016 Dec; 6():39032. PubMed ID: 27941949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.
    Spivak AM; Nell RA; Petersen M; Martins L; Sebahar P; Looper RE; Planelles V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.
    Jiang G; Mendes EA; Kaiser P; Sankaran-Walters S; Tang Y; Weber MG; Melcher GP; Thompson GR; Tanuri A; Pianowski LF; Wong JK; Dandekar S
    AIDS; 2014 Jul; 28(11):1555-66. PubMed ID: 24804860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.
    Spivak AM; Larragoite ET; Coletti ML; Macedo AB; Martins LJ; Bosque A; Planelles V
    Retrovirology; 2016 Dec; 13(1):88. PubMed ID: 27998278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.
    Venkatachari NJ; Zerbato JM; Jain S; Mancini AE; Chattopadhyay A; Sluis-Cremer N; Bar-Joseph Z; Ayyavoo V
    Retrovirology; 2015 Oct; 12():85. PubMed ID: 26438393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oocyte activation and latent HIV-1 reactivation: AMPK as a common mechanism of action linking the beginnings of life and the potential eradication of HIV-1.
    Finley J
    Med Hypotheses; 2016 Aug; 93():34-47. PubMed ID: 27372854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.
    Wang P; Lu P; Qu X; Shen Y; Zeng H; Zhu X; Zhu Y; Li X; Wu H; Xu J; Lu H; Ma Z; Zhu H
    Sci Rep; 2017 Aug; 7(1):9451. PubMed ID: 28842560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
    Spina CA; Anderson J; Archin NM; Bosque A; Chan J; Famiglietti M; Greene WC; Kashuba A; Lewin SR; Margolis DM; Mau M; Ruelas D; Saleh S; Shirakawa K; Siliciano RF; Singhania A; Soto PC; Terry VH; Verdin E; Woelk C; Wooden S; Xing S; Planelles V
    PLoS Pathog; 2013; 9(12):e1003834. PubMed ID: 24385908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
    Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
    EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Profiling of a Primary CD4
    Saha JM; Liu H; Hu PW; Nikolai BC; Wu H; Miao H; Rice AP
    AIDS Res Hum Retroviruses; 2018 Jan; 34(1):103-110. PubMed ID: 29084447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.